Image for Eculizumab

Eculizumab

Benoit, Knutr(Edited by)
See all formats and editions

Please note that the content of this book primarily consists of articles available from Wikipedia or other free sources online.

Eculizumab (INN and USAN, trade name Soliris) is a monoclonal antibody directed against the complement protein C5.

Eculizumab has been shown to be effective in treating paroxysmal nocturnal hemoglobinuria (PNH), a rare and sometimes life threatening disease of the blood, and is approved for this indication.

Eculizumab is a recombinant humanized monoclonal IgG2/4 antibody that specifically binds to the complement protein C5, inhibiting its cleavage by the C5 convertase which prevents the generation of the terminal complement complex C5b-9.

It is this terminal complement complex that causes intravascular hemolysis in people with (PNH).

Read More
Title Unavailable: Out of Print
Product Details
Dict
6200230730 / 9786200230737
Paperback / softback
04/01/2012
United States
56 pages, black & white illustrations
152 x 229 mm, 95 grams
General (US: Trade) Learn More